| 1  | Self-applied carrageenan-based gel to prevent human papillomavirus infection                  |
|----|---|
| 2  | in sexually active young women: Final analysis of efficacy and safety of a randomised         |
| 3  | controlled trial  |
| 4  |   |
| 5  | Cassandra Laurie, Mariam El-Zein, Sarah Botting-Provost, Joseph E. Tota, Pierre-Paul Tellier, |
| 6  | François Coutlée, Ann N. Burchell, Eduardo L. Franco  |
| 7  |   |
| 8  | Division of Cancer Epidemiology, McGill University, Montreal, Canada (C Laurie MSc; M         |
| 9  | El-Zein PhD; S Botting-Provost MSc; Prof E L Franco DrPH);                                    |
| 10 | Epidemiology Department, Merck & Co. Inc., Rahway, NJ, USA (J E Tota PhD);                    |
| 11 | Department of Family Medicine, McGill University, Montreal, Canada (P-P Tellier MD);          |
| 12 | Laboratoire de virologie moléculaire, Centre de recherche, Centre hospitalier de l'Université |
| 13 | de Montréal (CRCHUM), et Département de Microbiologie, infectiologie et Immunologie,          |
| 14 | Université de Montréal, Montréal, Canada (F Coutlée MD);                                      |
| 15 | and Department of Family and Community Medicine and MAP Centre for Urban Health               |
| 16 | Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto,     |
| 17 | Toronto, Canada (A N Burchell PhD)  |
| 18 |   |
| 19 | Correspondence to:  |
| 20 | Prof. Eduardo L Franco, Department of Oncology, McGill University, Montreal H4A 3T2, Canada   |
| 21 | eduardo.franco@mcgill.ca  |
| 22 |   |
| 23 | Abstract: 301 (300 max)   |
| 24 | Manuscript: 425 excluding research in context section (3000-4500 max)                         |
| 25 | Tables and figures: 4 tables and 2 figures (not specified)                                    |
| 26 | References: 29 (30 max)   |

# 27

#### ABSTRACT

# 28

# 29 Introduction

The Carrageenan-gel Against Transmission of Cervical Human papillomavirus trial's interim analysis (June 2017, n=277) demonstrated a 36% protective effect of carrageenan against incident

32 human papillomavirus (HPV) infections. We report the trial's final results on efficacy and safety

33 of a carrageenan-based gel in reducing HPV incidence and prevalence.

34

# 35 Methods

36 A phase IIB randomised, placebo-controlled trial, recruited healthy young women aged >18 37 primarily from health service clinics at two Canadian Universities in Montreal, Canada. 38 Participants were randomised (1:1) to a carrageenan-based or placebo gel to be self-applied every 39 other day for the first month and before/after intercourse. Primary outcomes were HPV typespecific incidence and clearance of prevalent infections. At each visit (months 0, 0.5, 1, 3, 6, 9, 40 41 12), participants provided questionnaire data and a self-collected vaginal sample (tested for 36 42 HPV types, Linear Array). Intention-to-treat analyses were conducted using Cox proportional 43 hazards regression models. Incidence and clearance analyses were restricted to participants with 44  $\geq 2$  visits. Trial registration:ISRCTN96104919.

45

# 46 Findings

461 participants (enrolled January 16<sup>th</sup>/2013–September 30<sup>th</sup>/2020) were randomised to 47 48 carrageenan (n=227) or placebo (n=234) arm. Incidence, clearance, and safety analyses included 49 429, 240, and 461 participants, respectively. We found 51.9% (108/208) of participants in 50 carrageenan and 66.5% (147/221) in placebo arm acquired  $\geq$ 1 HPV type (hazard ratio [HR] 0.63 51 [95% CI: 0.49-0.81]). Among participants who tested HPV-positive at baseline, clearance (two 52 consecutive HPV-negative visits following  $\geq 1$  positive visit) was comparable between groups; 53 31.8% (34/107) in carrageenan and 29.3% (39/133) in placebo arm cleared their infections (HR 54 1.16 [95% CI: 0.73-1.84]). Adverse events were reported by 34.8% (79/227) and 39.7% (93/234) 55 of participants in carrageenan and placebo arm (p<0.27), respectively.

56

57

# 58 Interpretation

- 59 Consistent with the interim analysis, use of a carrageenan-based gel resulted in a 37% reduction
- 60 in the risk of incident genital HPV infections in women. A carrageenan-based gel may complement
- 61 HPV vaccination.

# 62 Funding

- 63 Canadian Institute of Health Research (grants MOP-106610 and FDN-143347 to ELF),
- 64 CarraShield Labs Inc. (St Petersburg, FL) [provided gels in kind].

#### 65 Keywords

66 Carrageenan; Gel; HPV; Human papillomavirus; Microbicide; Randomized controlled trial.

#### **RESEARCH IN CONTEXT**

#### 67 Evidence before this study

We published in 2021 a narrative review summarizing carrageenan's preventive effect on human papillomavirus (HPV) based on results from 19 experimental research articles that reported on carrageenan's anti-HPV activity. Since publication and without applying language or date restriction, we identified four additional records based on a PubMed search using the keywords "carrageenan" and "human papillomavirus" or "HPV" up to January 9th, 2023.

73

Altogether, these records consist of ten *in vitro* (including 4 *ex vivo*), five *in vitro* and *in vivo*, three *in vivo*, and five clinical studies (including one post-hoc phase III randomised controlled trial [RCT], one observational study, one interim analysis of a phase IIB RCT in women, and two records for the interim analyses of a phase IIB RCT in men). Studies assessed carrageenan alone or in combination with other anti-microbial agents. The results from pre-clinical studies were consistent with a protective effect of carrageenan against HPV.

80

81 Overall, eight studies were conducted in humans. The samples collected were either 1) 82 cervicovaginal lavage samples to assess anti-HPV activity in vitro (in three ex vivo studies, two 83 being phase I RCTs), or 2) genital samples from women (post-hoc RCT [cervical], observational 84 study [sample type not reported], and RCT phase II [vaginal]) or anal samples from men (one 85 study of incidence and one of clearance). In the three ex vivo studies, intravaginal use of 86 carrageenan-containing gels was associated with strong anti-HPV activity. In a post-hoc sub study 87 of the trial, a lower HPV prevalence in the carrageenan compared to placebo arm was found at the 88 trial end, but only among the most compliant users (adjusted odds ratio [aOR] 0.62 [95% CI 0.41-89 0.94], n=348). There were, however, no baseline or intermediate measurements to assess HPV 90 status. An observational study reported that a carrageenan-based gel may accelerate clearance of 91 existing HPV infection (aOR 4.9 [95% CI 1.60-15.1], n=75). The interim analysis of the CATCH 92 study found a 36% protective effect of carrageenan against incident HPV infection(s) (HR 0.64 93 [95% CI 0.45 - 0.89], n=277). Conversely, a clinical trial conducted in men who have sex with men 94 did not demonstrate a protective effect of carrageenan on incidence (HR 1.21 [95% CI 0.86-1.70]), 95 or clearance (HR 0.84 [95% CI 0.31-2.27]) of anal HPV infections, and reported more adverse 96 events in the carrageenan (59.8%) relative to the placebo (39.8%) arm.

# 97 Added value of this study

98 The CATCH study is the first clinical trial designed to assess the efficacy of a carrageenan-based 99 gel in reducing the risk of incident and prevalent HPV infections in women. Results were 100 consistent when considering HPV subgenera and type-specific analyses. The addition of 101 carrageenan to a lubricant gel does not appear to impact gel tolerability.

102

# 103 Implications of all the available evidence

The results of the CATCH trial indicate that carrageenan-based gels could complement HPV vaccination in protecting against HPV-related diseases. Our findings of the clinical efficacy of carrageenan may encourage future research in this area. It would be important to further examine adherence by looking at determinants of adherence, explore the possibility of the addition of carrageenan to condoms, assess the impact of a carrageenan-based gel on anal HPV infections in women, and continue research in the area of multi-purpose prevention technology for agents against HPV, HIV, and other sexually transmitted infections.

#### INTRODUCTION

111 112

The most common sexually transmitted infection (STI) agent worldwide is human papillomavirus (HPV), which is a necessary cause of cervical cancer.<sup>1</sup> Globally, cervical cancer is the fourth most commonly diagnosed cancer in women, with an estimated 604,127 new cases and 341,831 deaths in 2020.<sup>2</sup> Elimination of cervical cancer is believed to be within our reach as per the World Health Organization's (WHO) 2020 call to eliminate cervical cancer through a three-pronged approach: 1) HPV vaccination of 90% of girls by age 15, 2) cervical cancer screening of 70% of women aged 35-45, and 3) treatment of 90% of women with cervical precancers and cancers.<sup>3</sup>

120

121 While HPV vaccination is a highly effective intervention for primary prevention of HPV, the 122 development, implementation, and maintenance of HPV vaccination programs across different 123 settings are not without their challenges, including the negative impact of the COVID-19 pandemic derailing the uptake of HPV vaccines, temporary HPV vaccine shortage, cold chain requirements, 124 125 and vaccine hesitancy.<sup>4</sup> Although the global HPV vaccine supply is estimated to meet global demand,<sup>5</sup> the HPV vaccine shortage highlights the need for the development of complementary 126 127 primary prevention methods. The use of a personal self-administered gel may support the WHO's 128 goals to eliminate cervical cancer.

129

130 Carrageenan, an anionic polymer derived from red algae, previously showed promise as a potent anti-HPV inhibitor in vitro and in vivo,<sup>6</sup> and has a good safety profile for vaginal use.<sup>7</sup> The 131 132 Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) trial was 133 specifically designed to evaluate the efficacy of a carrageenan-based gel against incident and 134 prevalent HPV infections.<sup>8</sup> Based on the interim analysis (June 2017, N=277), carrageenan-gel use 135 was associated with a 36% protective effect against incident human papillomavirus (HPV) 136 infections compared to placebo gel use.<sup>9</sup> Anti-microbial agents, such as carrageenan, represent a 137 promising area of research in STI prevention. We now report the results of the final analysis of 138 efficacy and safety of a carrageenan-based gel in reducing HPV incidence and prevalence of 139 genital HPV among sexually-active young women.

- 140
- 141

142

#### **METHODS**

The trial findings are reported following the CONSORT (Consolidated Standards of Reporting
 Trials) 2010 checklist.<sup>10</sup>

145

# 146 Study design and population

147 The CATCH trial is an exploratory phase IIB block-randomised, placebo-controlled trial. The full 148 details of the study protocol and data collection were previously described.<sup>13</sup> We recruited female 149 university students through McGill Health Service Clinic, Concordia Health Services, the Centre 150 intégré de santé et de services sociaux de la Montérégie-Centre-Territoire Champlain-Charles-Le 151 Movne, and (as of September 2018) at the Gerald Bronfman Department of Oncology at the 152 Division of Cancer Epidemiology of McGill University, Québec, Canada. Enrollment and follow-153 up visits were conducted at months 0.5, 1, 3, 6, 9, and 12. Study data were securely stored by LFC 154 hosting until December 15, 2019. Thereafter, data were collected and stored using REDCap (Research Electronic Data Capture) tools.<sup>11,12</sup> The study received ethical approval from McGill 155 156 University, Centre Hospitalier de l'Université de Montréal, Concordia University, and the Centre 157 intégré de santé et de services sociaux de la Montérégie-Centre-Territoire Champlain-Charles-Le 158 Moyne. Participants gave written informed consent (and e-consent as of September 5, 2019), 159 which was administered by the study nurse.

160

#### 161 Eligibility

162 Eligible women to participate were those aged 18 years and older, living in Montreal and planning 163 to remain in Montreal for at least the next year, who had vaginal sex with a male partner during 164 the past 3 months and expect do so again in the next 3 months (regardless of whether or not the 165 male partner(s) will change), not currently in a relationship that has lasted longer than 6 months 166 (i.e. likely to be exposed to new HPV infections), willing to follow study instructions and attend 167 follow-up visits for 12 months, who understand French or English, and who use a medically 168 acceptable method of contraception and intend to use it for the duration of the trial. Women were 169 considered ineligible based on the following exclusion criteria: have had a hysterectomy, have a 170 history of cervical lesions/cancer or genital warts, pregnant or planning to immediately become 171 pregnant, currently breast-feeding, had a recent (within the last 6 weeks) pregnancy, abortion, or 172 genital surgery, have human immunodeficiency virus (HIV) infection, have a known allergy or

hypersensitivity to vaginal lubricants and have allergy to any of the ingredients of the study productor placebo, have participated in any research studies (past 3 months) related to HPV or cervical

- 175 cancer, or have participated in any research studies (past 3 months) that require taking medications
- 176 or supplements, undergo medical tests or procedures, or undertake dietary or exercise regimens.
- 177

# 178 Randomisation and masking

Participants were randomised (1:1) to a carrageenan-based or placebo gel by the study nurse, using computer-assisted block randomisation with a block-size of 8. The intervention and placebo gels were packaged in identical containers, except for the product code label; four different codes were used for the intervention gel and an additional four for the control. The participant, study nurses, and laboratory technicians were blinded to group assignment.

184

# 185 **Procedures and data/samples collection**

186 Participants were instructed to apply the study gel every other day for the first month as well as 187 before (and after as of October 26, 2015) each vaginal intercourse. Approximately 5-10mL of the gel was to be applied to the vagina, penis, and/or condom. STI protection methods (e.g., condoms) 188 189 were encouraged. Participants were asked to refrain from intercourse at least 48 hours prior to their 190 follow-up visits. Both study gels are commercially available (Divine9 and Divine), made by 191 CarraShield Labs Inc. (St Petersburg, FL). The study gels are identical; both are water-based, clear, 192 odourless, tasteless, and of a similar viscosity. The distinguishing feature is the inclusion of 193 carrageenan in the intervention gel.

194

195 At enrollment and each follow-up visit, participants completed a computer-assisted questionnaire 196 on sociodemographic characteristics, smoking and alcohol use, medical and sexual history (only 197 at enrollment), sexual activity and study gel use since last visit (only at follow-up), and condom 198 and lubricant use (both enrollment and follow-up). In addition, a daily online calendar included 199 questions on sexual behaviour, gel use, and adverse events (AEs). Participants could enter and 200 modify calendar information for the seven previous days, which required them to log in at least 201 once a week with a username and password. Additional details are provided in Supplementary 202 Section 1: Figure 1 and Tables 1A-1C.

203

A self-collected vaginal sample was obtained at each study visit. Samples were tested using Linear Array (Roche Molecular Diagnostics, Branchburg, NJ) for detection and genotyping of 36 HPV types.<sup>13</sup> Samples were tested for beta-globin prior to genotyping. Of 2510 samples, 19 were unavailable (12 samples were beta-globin negative and 7 were mishandled). Carrageenan as used in the clinical protocol above was not shown to inhibit HPV detection in genital samples.<sup>14</sup>

209

# 210 Outcomes

The two primary outcomes were 1) presence of a newly detected vaginal HPV infection that was not detected at enrollment, and 2) HPV type-specific clearance of infection(s) detected at enrollment. The secondary outcome was adherence (i.e., compliance) to the intervention measured using data from the daily online calendar. Adherent participants were defined as those who used the gel as recommended in >50% of all intercourse acts. While not pre-specified, we also assessed 1) adherence to gel use defined as cumulative adherence prior to censoring or failure, and 2) safety of the study gels by compiling all adverse events that were reported.

218

#### 219 Statistical analysis

Details on sample size calculation in the CATCH protocol showed that the required sample size was 463 for incidence and 388 for clearance analyses.<sup>8</sup> Based on oncogenic risk and tissue tropism, we grouped HPV types into subgenera; low-risk types in subgenus 1: HPVs 6, 11, 40, 42, 44, and 54; high-risk types in subgenus 2: HPVs 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, and 82; and commensal HPVs in subgenus 3: HPVs 61, 62, 71, 72, 81, 83, 84, and 89.<sup>15-17</sup> Baseline visits with missing HPV data (n=3) were imputed based on data at the second visit (on average, 14 days after the first visit).

227

Adherence to the intervention was defined as the number of gel uses divided by the number of vaginal intercourses in the seven days prior to the study visit (from follow-up survey data) and between consecutive study visits (from calendar data). We compared adherence between groups and study visits. Due to (non-significant) imbalances in baseline HPV vaccination status between arms and discrepancies in reporting of vaccination status between screening (pre-enrollment) and the baseline survey (at enrollment), we validated participants' vaccination status by either confirming their status via email or (in the case of no email reply) by using the date of vaccination

reported in their baseline or follow-up survey (Supplementary Section 2: Figure 2 and Tables 2A-236 2C).

237

238 Cox proportional hazards regression models were used to evaluate the efficacy of carrageenan in 239 reducing vaginal HPV incidence/detection and prevalence. Missing HPV data for follow-up visits 240 were censored in incidence and clearance analyses. Incidence analyses, performed by any HPV 241 positivity (if a participant was positive for one or more HPV types at baseline, they remain at risk 242 of acquiring HPV types absent at baseline) and subgenera (separate analyses done for each of the 243 three subgenera), included participants who had at least 1 follow-up visit. We performed sub-group 244 analyses to compare the intervention effects according to main baseline characteristics and 245 cumulative adherence to gel use prior to failure (new detection of an HPV type) or censoring.

246

Participants were included in clearance analyses if they had at least two study visits and were HPVpositive at baseline. We considered two definitions of clearance: liberal (one HPV-negative visit following at least one HPV-positive visit) and conservative (two consecutive HPV-negative visits following at least one HPV-positive visit). We considered time to 1) clearance of all baseline HPV infections and 2) first clearance of any baseline HPV infection.

252

Analyses were also done at the HPV-level, where the unit of analysis was each individual HPV type. The models were stratified by HPV type and clustered by participant. For incidence analyses, participants were considered at risk for any HPV type absent at baseline, where each participant could contribute up to 36 observations, each corresponding to an HPV type. For HPV-level clearance analyses, participants were considered at risk for clearing any of their baseline HPV infections.

259

To assess safety of the study gels, we tabulated self-reported AEs and/or reactions that were recorded by means of the 1) *daily calendar*, 2) *follow-up survey* administered at each follow-up visit, 3) *adverse event module (nurse report)* during follow-up visits, and/or 4) reporting of an adverse event during *adverse event follow-up*. AEs reported in the daily calendar were graded (mild, moderate, or severe) by participants.

265

Data management and analyses were done in SAS V9.4 and Stata version 17, respectively. The trial was registered (ISRCTN96104919) and approved by Health Canada (authorization file number 169160). A data safety and monitoring board reviewed and recommended publication of the previously published interim analysis,<sup>9</sup> as well as the final trial results reported herein.

270

# 271 Role of funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

274 275

#### **RESULTS**

276 Recruitment took place between January 16th, 2013 and October 30th, 2020. As shown in Figure 277 1, 1016 participants were assessed for eligibility. Of these, 461 were randomised into the 278 carrageenan (n=227) and placebo (n=234) arms. Study visits 2-7 were completed by 461, 429, 399, 279 362, 318, 291, and 257 participants, respectively. Overall, 429, 240, and 461 participants were 280 included in the incidence, clearance, and safety analyses, respectively. Supplementary Figure 3 281 shows the distribution of time between baseline and subsequent visits compared to the study 282 schedule. While there were variations between the actual and planned study schedule, little 283 difference was observed between intervention arms.

284 Baseline characteristics of study participants are shown in Table 1. The median age was 23.0 in 285 the carrageenan and 21.9 in the placebo arm. Most participants were Canadian, single, never 286 smokers, had less than 5 lifetime sexual partners, and had 1 sexual partner in the past month. The 287 median age at first intercourse was 17. More participants in placebo (60.3%) compared to 288 carrageenan (50.7%) arm were infected with any HPV type at baseline, which was consistent by 289 subgenera. Detailed HPV prevalence data at each study visit are shown for carrageenan and 290 placebo arms in Supplementary Tables 3A and B, respectively. Fewer participants in the 291 carrageenan (26.1%) compared to placebo arm (31.7%) reported ever having anal intercourse 292 during follow-up. Fewer participants in carrageenan (42.7%) compared to placebo (51.3%) arm 293 reported being vaccinated against HPV. The difference in vaccination status between arms was 294 smaller based on validated vaccination status; 42.3% of participants in carrageenan and 49.2% in 295 placebo arm reported receiving the HPV vaccine.

Follow-up characteristics of the participants are shown in Supplementary Table 4. The median overall follow-up time was  $12 \cdot 2$  months. At the observation level (observations between two consecutive study visits), adherence was comparable between arms;  $26 \cdot 0\%$  of participants in carrageenan and  $26 \cdot 9\%$  in placebo arm reported >75% adherence in the 7 days preceding each visit based on data from the follow-up surveys.

As shown in Table 2, fewer participants in carrageenan (51.9%, 108/208) acquired an incident HPV infection compared to placebo (66.5%, 147/221) arm (HR 0.63, 95% CI 0.49-0.81). This effect was consistently observed in participant-level analyses by subgenera (HRs ranged from 0.58-0.70) and in the HPV-level analysis (HR 0.65, 95% CI 0.50-0.83). Figure 2 shows the cumulative incidence of HPV by intervention arm; participant- (Fig2A) and HPV- (Fig2B) level results were consistent with a protective effect of carrageenan against incident HPV infections.

307 Table 3 shows time to clearance of all HPV types and time to clearance of the first cleared HPV 308 infection by clearance definition (liberal and conservative). The effect estimates were consistently 309 greater than the null value but never reached statistical significance, irrespective of the analysis 310 level, clearance outcome, or clearance definition. Based on liberal clearance definition of all HPV 311 types, 57.9% (62/107) of participants cleared all their baseline infections in carrageenan and 312 49.6% (66/133) in placebo arm, corresponding to a HR of 1.41 (95% CI 0.99-2.00). By applying 313 the conservative definition, the HR was 1.16 (95% CI 0.73-1.84). When considering only the first 314 cleared infection, 79.4% (85/107) cleared at least 1 HPV infection in the carrageenan and 79.0%315 (105/133) in the placebo arm (HR 1.03, 95% CI 0.77-1.38) for the liberal definition; these values 316 were 62.6% (67/107) and 60.9% (81/133) (HR 1.04, 95% CI 0.75-1.44) for conservative 317 clearance, respectively. No remarkable differences were observed when considering time to 318 clearance of individual HPV types; 66.8% cleared at least 1 HPV type in the carrageenan and 319 65.7% in the placebo arm (HR 1.17, 95% CI 0.90-1.51) for the liberal definition, and 45.0%320 cleared at least 1 HPV type in the carrageenan and 45.7% in the placebo arm (HR 1.10, 95% CI 321 0.84-1.43) for the conservative definition.

Overall, there was a similar proportion of AEs reported in each arm: 34.8% (79/227) in the carrageenan and 39.7% in the placebo arm (93/234) (Table 4). Those most frequently reported were vaginal yeast infection, itching, burning or pain in the genital area, and bacterial vaginosis.

325 Of participants who reported an AE in the daily calendar, 24.3% (9/37) in carrageenan and 30.8%326 (12/39) in placebo arm graded their AEs as severe (Supplementary Table 5); the most common 327 severe AE was "itching, burning or pain in the genital area". We did not observe a higher 328 proportion of withdrawals among participants who reported adverse events nor among participants 329 who reported difficulties using the study gel (Supplementary Table 6). The proportion of 330 participants reporting difficulties with the study gel before, during, or after intercourse was similar 331 between arms (77.2% [159/204]) in the carrageenan and 80.7% [176/218] in the placebo arm); the 332 most frequently reported difficulties were not having the CATCH gel at the time of intercourse or 333 forgetting to use the CATCH gel (Supplementary Table 7).

334 No differences were observed in sub-group analyses by baseline characteristics (age, ethnicity, 335 marital status, smoking status, age at first intercourse, lifetime sexual partners, sex partners in the 336 last month, HPV status at baseline, and vaccination status) and cumulative adherence to gel use 337 (Supplementary Figure 4). There was also no evidence of a dose-response relationship based on 338 cumulative adherence to gel use prior to failure or censoring, irrespective of data used (calendar 339 data or follow-up survey data) nor categorization (binary [ $<50, \geq 50$ ] or categorical), nor was a 340 more protective effect observed when analyses were restricted to participants with an overall 341 adherence >50% (per-protocol analysis) [Supplementary Table 8].

# DISCUSSION

We found a 37% protective effect of carrageenan-gel use against incident HPV infections compared to placebo gel use, but no acceleration of clearance of existing HPV infections. Adherence was balanced between arms, and the study gels were generally well tolerated. These findings corroborate the interim analysis results, published in 2019, which reported a nearly identical estimate of a 36% protective effect of carrageenan against incident HPV infection (HR 0.64 [95% CI 0.45-0.89], N=277).<sup>9</sup>

351

342 343

344

Clinical studies, and trials in particular, on the efficacy of carrageenan-based gels against HPV infection are scarce (Supplementary Table 9). The CATCH study represents the first phase IIB trial specifically designed to assess the efficacy of carrageenan against incident and prevalent HPV infections. Prior to its initiation, a post-hoc analysis of a trial originally designed to assess

356 carrageenan's anti-HIV effect found a lower prevalence of HPV at the trial's end in compliant 357 users of Carraguard<sup>®</sup> (carrageenan gel) compared to compliant placebo (methylcellulose) gel 358 users (aOR 0.62 [95% CI 0.41-0.94], N=348) adjusted for site, STI, average coital frequency, 359 longer time in study, abnormal pap smear, baseline condom use, age by relationship, and 360 promiscuity by condom use; however, this was a subgroup analysis, and there were no baseline nor intermediate measures of HPV to use as a reference.<sup>18</sup> Other smaller trials, evaluated 361 362 carrageenan's anti-HPV activity in vitro from a cervicovaginal lavage using combination products of MIV-150, zinc acetate dihydrate, and carrageenan (20 participants),<sup>19</sup> as well as carrageenan 363 and griffithsin (13 participants),<sup>20</sup> demonstrating anti-HPV activity in all or the majority of 364 samples. Moreover, while there was evidence for carrageenan preventing vaginal HPV infections, 365 366 carrageenan-based gels have not been shown to be effective against anal HPV infections in men,<sup>21</sup> 367 possibly due in part to anatomical differences between the vagina and anal canal, as well as 368 histological differences: stratified squamous in the vagina and simple columnar and stratified 369 squamous epithelium in the anal canal.

370

371 Adherence to the intervention was balanced by arm. We would expect to see that more compliant 372 participants would have increased protection against incident HPV infections. Another trial, 373 assessing Carraguard®'s anti-HPV activity post-hoc, found a protective effect of carrageenan against prevalent HPV infections but only among adherent users (20.3%, 348/1718).<sup>18</sup> However, 374 375 in the CATCH trial, a dose-response relationship was not observed. This could be due to 376 misclassification of adherence. For example, during the first month of participation, participants 377 were asked to apply the gel every other day for the purpose of assessing if the gel could increase 378 clearance of existing infections. If a participant reported vaginal intercourse but no gel use during 379 vaginal intercourse, but used the gel outside of vaginal intercourse, she would be classified as non-380 compliant but may have been offered some protection against HPV infection due to residual 381 carrageenan gel in the vaginal canal. One study showed that carrageenan is present 8-24 hours 382 after Carraguard® gel application for the majority of participants (75%, 12/16), based on cervicovaginal lavage samples.<sup>22</sup> In a study that tested Divine9<sup>TM</sup>, carrageenan was detected in 383 mouse vaginal washes up to 4 hours after application, but not after 24 hours.<sup>23</sup> Another study 384 385 testing Divine9, but in cervicovaginal lavage samples, detected carrageenan in the majority (78%) of samples 8 hours after gel application.<sup>24</sup> Based on these studies, it is reasonable to expect that 386

387 there would at least be some anti-HPV activity several hours post-application, suggesting that if a 388 woman applied the gel in the morning and had intercourse in the evening that she could have been 389 offered some protection.

390

391 The assessment of gel safety, comparing Divine9 (intervention) to Divine (placebo), found 37% 392 of participants reported AEs. A large trial (N=6202), comparing Carraguard® (a carrageenan-393 based gel) to methylcellulose with up to 2 years of follow-up, reported that 23% of participants 394 experienced AEs.<sup>7</sup> This indicates worse tolerability of the study gels used in the CATCH trial 395 compared to the Carraguard<sup>®</sup> trial. Over the course of follow-up, 16.5% of CATCH participants 396 reported a vaginal yeast infection and 5.6% reported having bacterial vaginosis. These proportions 397 are lower than those reported in a phase II safety trial (N=165), comparing Carraguard® to 398 methylcellulose, where 38% of participants reported having a yeast infection and 22% reported having bacterial vaginosis over follow-up.<sup>25</sup> The difference may be explained by the nature of 399 400 reporting; these conditions were self-reported in the CATCH study, whereas they were 401 systematically tested for at each study visit in the safety trial.<sup>25</sup> The nature of reporting may have 402 led to detection bias (i.e., systematically testing for these conditions leading to more detections), 403 as bacterial vaginosis can be asymptomatic and therefore not self-reported by participants.

404

405 While the study gels were approved by Health Canada and have received 510(k) clearance by the 406 United Stated Food and Drug Administration (FDA), they are hyperosmolal and therefore do not meet the current WHO recommendation for osmolality (<1200mOsM/kg).<sup>26</sup> Hyperosmolality and 407 408 certain ingredients, such as polyquaternium-15 and nonoxynol-9, have been shown to increase 409 epithelial exfoliation, or sloughing, and cause cytotoxicity, potentially increasing the risk of acquiring certain STIs.<sup>26</sup> However, these products remain commercially available. Studying the 410 411 tolerability of lubricants and identifying the ingredients responsible for causing irritation is a 412 challenge, as conclusive evidence on the safety and harms associated with personal lubricant is 413 difficult to generate due to a high number of potential confounders, such as condom use, frequency 414 of sex, and differences in reporting of lubricant use. For example, a lack of evidence of harm 415 caused by polyquaternium led the WHO in 2020 to revert its 2012 recommendation to avoid polyquaternium in personal lubricants.<sup>26</sup> The study gels were later reformulated using the same 416 417 type of carrageenan at the same concentration but with adjustments to inactive ingredients to meet

the WHO recommendations on osmolality. The reformulated gel was not used in the CATCH trial(Dean Fresonke, Personal communication).

420

421 The trial was not without limitations. First, gel use was self-reported, which may be subject to 422 social desirability bias if participants tended to overreport adherence to gel use. This could 423 possibly lead to misclassification of exposure and would be expected to bias the estimate towards 424 the null in adherence analyses. Second, the proportion of AEs experienced by participants in the 425 carrageenan arm might have been underestimated. Comparing participants in carrageenan to 426 placebo arm, there were fewer participants randomised (227 versus 234), more participants who 427 discontinued participation after their first visit (19/227 versus 13/234), and fewer participants who 428 reported AEs (19/227 versus 9/234), leading to fewer participants available to report AEs in the 429 carrageenan arm. Thirdly, the placebo gel, while identical to the intervention gel except for the 430 addition of carrageenan, may not be a true placebo, as it could have anti-HPV activity that would 431 bias the estimate towards the null. While AEs were balanced between arms, this does not exclude 432 the possibility that the study gels could have caused more irritation than would be expected from 433 other common lubricants or methylcellulose, which has been used in other microbicide trials. The 434 greatest strength of the trial is that it is the first phase IIB randomized controlled trial designed to 435 assess the efficacy of a carrageenan-based gel on incident and prevalent HPV infections. A strength 436 of having two identical gels, with the exception of the addition of carrageenan, is that the protective 437 effect observed can be attributed to the presence of carrageenan. An additional strength is the 438 collection of detailed information over time, in particular the implementation of a daily calendar to obtain details of gel use, sexual activity, and adverse events, which lead to the collection of 439 440 95,327 observations. HPV positivity was assessed by detecting 36 different HPV types using the 441 Linear Array, which allowed us to assess genotype-specific HPV incidence among HPV-positive 442 women.

443

It has been hypothesized that carrageenan works by binding directly to the HPV capsid, thereby preventing HPV from binding to heparan sulfate proteoglycan (HSPG), which is a key step in the infection process on the basement membrane.<sup>27</sup> Carrageenan has also been shown to prevent attachment of HPV to human sperm,<sup>28</sup> potentially preventing dispersion of HPV within the vaginal

canal. Carrageenan may also act through a secondary mechanism independent of HSPG, where
carrageenan prevents the virus from binding secondary receptors during the infection process.<sup>28,29</sup>
Multiple mechanisms may be responsible for the anti-HPV activity demonstrated in the CATCH
study.

452

This research supports current investigations on the use and utility of carrageenan co-formulated with other anti-microbials (such as griffithsin and carrageenan) in multi-prevention technologies,<sup>20</sup> as well as with MIV-150, consisting of an anti-HIV agent, zinc acetate and carrageenan.<sup>19</sup> To improve adherence to the intervention and encourage STI protection in general, it may be equally important to also study use of carrageenan-based gels in pre-packaged condoms.

458

Despite the high osmolality of the study gels, carrageenan was protective against incident HPV infections in women. Given that carrageenan-based gels have not demonstrated efficacy in preventing anal HPV infections in men, it would be necessary to conduct a gel tolerability study with the reformulated carrageenan-based gel at the correct osmolality in both women and men that include measurements of anal HPV.

464

In conclusion, carrageenan compared to placebo gel use was associated with a reduction in incident
HPV infections. Topical microbicides against HPV, such as carrageenan-based gels, may have
utility as a complement to HPV vaccination among sexually active women.

468

# 469 **Contributors**

470 The authors contributed to: conceptualisation (ELF, ANB, FC, P-PT, JET, CL, MZ); data curation 471 (MZ, CL, SBP); formal analysis (CL); funding acquisition (ELF, ANB, FC, P-PT, JET); 472 investigation (ELF, MZ, CL, SBP, FC), methodology (ELF, ANB, FC, P-PT, JET, MZ, CL); 473 project administration (ELF, MZ); resources (ELF, MZ, FC); supervision (ELF, MZ); validation 474 (CL, SBP); visualisation (CL); writing – original draft (CL); and writing – reviewing and editing 475 (ELF, ANB, FC, P-PT, JET, MZ, SBP, CL). CL and SBP directly assessed and verified the 476 underlying data. All authors had full access to the study data and had the final responsibility to 477 decide to submit for publication.

478

# 479 **Declaration of interests**

480 ELF reports grants and personal fees from Merck, grants, personal fees and non-financial support 481 from Roche, and personal fees from GSK, outside the submitted work. ELF and MZ hold a patent 482 related to the discovery "DNA methylation markers for early detection of cervical cancer", 483 registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, 484 Canada (October 2018). FC reports grants from Réseau FRQS-SIDA during the conduct of the 485 study and grants to his institution for HPV-related work from Merck Sharp and Dome, Roche 486 Diagnostics and Becton Dickinson, outside of the submitted work. JET is an employee of Merck 487 Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, NJ, USA. P-PT, ANB, SBP, 488 and CL have nothing relevant to this article to declare.

489

## 490 Data sharing

The sample code used to generate the results are available in the McGill Dataverse repository (<u>https://doi.org/10.5683/SP3/0DS6FP</u>). Following publication, the anonymized study data and a codebook will be made also available. The study protocol and accompanying documents, such as the informed consent form were previously published.<sup>8</sup>

495

# 496 Acknowledgements

The study was funded by the Canadian Institutes of Health Research (grant number MOP-106610 and grant FDN-143347 to ELF). CarraShield Labs Inc. (St Petersburg, FL) provided the gels inkind. CarraShield Labs Inc was not involved in the design of the study, data collection, analyses, and interpretation of trial results. ANB is a Canada Research Chair in Sexually Transmitted Infection Prevention; she also receives salary support from a Non-Clinician Scientist Award, Department of Family and Community Medicine, Faculty of Medicine, University of Toronto.

We wish to thank study participants, employees of the CATCH study, and laboratory research assistants. We also acknowledge the members of the Data Safety and Monitoring Board who evaluated the safety and efficacy of the CATCH study at the interim and final analysis stages.

# 507 **REFERENCES**

- de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype
   distribution of cervical human papillomavirus DNA in women with normal cytology: a meta analysis. *Lancet Infect Dis* 2007; 7: 453–9.
- 511 2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN
- 512 Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J*513 *Clin* 2021; **71**(3): 209–49.
- 514 3. WHO. A cervical cancer-free future: First-ever global commitment to eliminate a cancer.
- 515 2020. <u>https://www.who.int/news/item/17-11-2020-a-cervical-cancer-free-future-first-ever-</u>
- 516 global-commitment-to-eliminate-a-cancer#:~:text=eliminate%20a%20cancer-
- 517 <u>A%20cervical%20cancer%2Dfree%20future%3A%20First%2Dever%20global,commitment%2</u>
- 518 <u>0to%20eliminate%20a%20cancer&text=WHO's%20Global%20Strategy%20to,%3A%20vaccina</u>
- 519 <u>tion%2C%20screening%20and%20treatment</u>. (accessed December 26, 2022).
- 520 4. Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human 521 Papillomavirus Vaccination after COVID-19. *JNCI Cancer Spectr* 2021; **5**.
- 522 5. WHO. Global Market Study HPV (Working Document) March 2022. 2022.
- 523 https://cdn.who.int/media/docs/default-source/immunization/mi4a/who-mi4a-global-market-
- 524 <u>study-hpv.pdf?sfvrsn=649561b3\_1&download=true</u> (accessed December 26, 2022).
- 525 6. Laurie C, El-Zein M, Coutlée F, de Pokomandy A, Franco EL. Carrageenan as a
- 526 preventive agent against human papillomavirus infection. *Sex Transm Dis* 2021; **48**: 458–65.
- 527 7. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of
- HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; **372**: 1977–87.
- 530 8. Laurie C, Tota JE, El-Zein M, et al. Design and methods for the Carrageenan-gel Against
  531 Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial.
  532 *Contemp Clin Trials* 2021; **110**: 106560.
- Magnan S, Tota JE, El-Zein M, et al. Efficacy of a Carrageenan gel Against Transmission
  of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled,
  phase 2B trial. *Clinic Microbiol Infect* 2019; 25: 210–6.
- 536 10. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: Updated
  537 Guidelines for Reporting Parallel Group Randomized Trials. *Ann Intern Med* 2010; **152**(11):
  538 726–32.
- 539 11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 540 data capture (REDCap)—A metadata-driven methodology and workflow process for providing 541 translational research informatics support. *J Biomed Inform* 2009; **42**: 377–81.
- 542 12. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an
- 543 international community of software platform partners. *J Biomed Inform* 2019; **95**: 103208.
- 544 13. Coutlée F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human
- papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV
   genotyping test. *J Clin Microbiol* 2006; **44**: 1998–2006.
- 547 14. Laurie C, El-Zein M, Franco EL, Coutlée F. Assessment of the possible inhibitory effect
- 548 of carrageenan in human papillomavirus DNA testing by polymerase chain reaction
- 549 amplification. *J Med Virol* 2021; **93**: 6408–11.
- 550 15. Shaw E, Ramanakumar AV, El-Zein M, et al. Reproductive and genital health and risk of
- cervical human papillomavirus infection: Results from the Ludwig-McGill cohort study. *BMC*
- 552 Infect Dis 2016; **16**: 116.

- 553 16. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human
- papillomavirus types: addressing the limits of epidemiology at the borderline. *Infect Agent Cancer* 2009; 4: 8.
- 556 17. Schiffman M, Herrero R, DeSalle R, et al. The carcinogenicity of human papillomavirus 557 types reflects viral evolution. *Virology* 2005; **337**: 76–84.
- 558 18. Marais D, Gawarecki D, Allan B, et al. The effectiveness of Carraguard, a vaginal
- 559 microbicide, in protecting women against high-risk human papillomavirus infection. *Antivir Ther* 560 2011; **16**: 1219–26.
- 561 19. Friedland BA, Hoesley CJ, Plagianos M, et al. First-in-Human Trial of MIV-150 and
- 562 Zinc Acetate Coformulated in a Carrageenan Gel. *J Acquir Immune Defic Syndr* 2016; **73**: 489–
  563 96.
- 564 20. Teleshova N, Keller MJ, Romero JAF, et al. Results of a phase 1, randomized,
- placebocontrolled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
   *PLoS One* 2022; **17**: e0261775.
- 567 21. Laurie C, El-Zein M, Tota JE, et al. Efficacy of a carrageenan gel in preventing anal
- human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to
   Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. Sex Transm
- 570 *Infect* 2021; **98**: 239–46.
- 571 22. Haaland RE, Chaowanachan T, Evans-Strickfaden T, et al. Carrageenan-based gel retains
- 572 limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women
- 573 enrolled in a phase I safety trial. *J Acquir Immune Defic Syndr* 2012; **61**: e71–3.
- 574 23. Rodriguez A, Kleinbeck K, Mizenina O, et al. In vitro and in vivo evaluation of two 575 carrageenan-based formulations to prevent HPV acquisition. *Antiviral Res* 2014; **108**: 88–93.
- 576 24. Novetsky AP, Keller MJ, Gradissimo A, et al. In vitro inhibition of human
- papillomavirus following use of a carrageenan-containing vaginal gel. *Gynecol Oncol* 2016; 143:
  313–8.
- 579 25. Kilmarx PH, van de Wijgert JHHM, Chaikummao S, et al. Safety and Acceptability of
  580 the Candidate Microbicide Carraguard in Thai Women. *J Acquir Immune Defic Syndr* 2006; 43:
  581 327–34.
- 582 26. Laurie C, Franco E. The potential harms of personal lubricants. *DST-J* 2020; **32**: 1–4.
- 583 27. Buck CB, Thompson CD, Roberts JN, et al. Carrageenan is a potent inhibitor of 584 papillomavirus infection. *PLoS Pathog* 2006; **2**: e69.
- 585 28. Perez-Andino J, Buck CB, Ribbeck K, Pérez-Andino J, Buck CB, Ribbeck K. Adsorption 586 of human papillomavirus 16 to live human sperm. *PLoS One* 2009; **4**: e5847.
- 587 29. Wang JW, Jagu S, Kwak K, et al. Preparation and properties of a papillomavirus
- 588 infectious intermediate and its utility for neutralization studies. *Virology* 2014; **449**: 304–16.
- 589

|   | Carrageenan<br>(n=227) | Placebo<br>(n=234) |
|---|------------------------|--------------------|
| Age – years   |                        |                    |
| Mean (SD)   | 25.5 (7.4)             | 23.4 (5.4)         |
| Median (IQR)  | 23.0 (7.4)             | 21.9 (5.3)         |
| Range   | 18.3-68.5              | 18.1-44.2          |
| Ethnicity, n (%)  |                        |                    |
| French Canadian   | 53 (23.4)              | 47 (20.1)          |
| English Canadian  | 62 (27.3)              | 68 (29.1)          |
| Black Canadian  | 14 (6.2)               | 15 (6.4)           |
| Latin American  | 22 (9.7)               | 22 (9.4)           |
| South Asian   | 9 (4.0)                | 7 (3.0)            |
| East Asian  | 16 (7.1)               | 24 (10.3)          |
| Other or not reported                                     | 51 (22.5)              | 51 (21.8)          |
| Marital status, n (%)                                     |                        |                    |
| Single  | 145 (63.9)             | 160 (68.4)         |
| Living with a partner or married                          | 22 (9.7)               | 23 (9.8)           |
| Divorced, separated, or widowed                           | 60 (26.4)              | 51 (21.8)          |
| Smoking status, n (%) <sup>a</sup>                        |                        |                    |
| Never   | 157 (69.2)             | 147 (62.8)         |
| Former  | 50 (22.0)              | 59 (25.2)          |
| Current   | 19 (8.4)               | 27 (11.5)          |
| Age at first intercourse, years                           |                        |                    |
| Mean (SD)   | 17.5 (3.0)             | 16.9 (2.2)         |
| Median (IQR)  | 17 (3)                 | 17 (2)             |
| Range   | 13-28                  | 12-23              |
| Not reported, n   | 5                      | 5                  |
| Lifetime sex partners – quantiles, n (%)                  |                        |                    |
| <5  | 61 (26.9)              | 60 (25.6)          |
| 5-7   | 43 (18.9)              | 35 (15.0)          |
| 8-11  | 37 (16.3)              | 47 (20.1)          |
| 12-20   | 47 (20.7)              | 50 (21.4)          |
| ≥21   | 39 (17.2)              | 42 (18.0)          |
| No. of sex partners in the past month, n (%) <sup>b</sup> |                        |                    |
| 0   | 42 (18.5)              | 36 (15.5)          |
| 1   | 144 (63.4)             | 144 (61.8)         |
| $\geq 2$  | 41 (18.1)              | 53 (22.8)          |
| Anal intercourse in the past month, n (%) <sup>c</sup>    |                        |                    |
| Yes   | 25 (11.0)              | 26 (11.2)          |
| No  | 202 (89.0)             | 206 (88.8)         |
| HPV DNA status, n (%)                                     |                        |                    |

# Table 1. Baseline characteristics of participants, by study arm

| A LIDY/d  | 115 (50.7) | 141 (60.2) |
|---|------------|------------|
| Any HPV <sup>d</sup>                                  | 115 (50.7) | 141 (60.3) |
| Negative  | 109 (48.0) | 93 (39.7)  |
| Missing PCR results <sup>e</sup>                      | 3 (1.32)   | 0 (0)      |
| Subgenus 1 <sup>f</sup>                               | 38 (17.0)  | 55 (23.5)  |
| Subgenus 2 <sup>g</sup>                               | 96 (42.9)  | 114 (48.7) |
| Subgenus 3 <sup>h</sup>                               | 60 (26.8)  | 76 (32.5)  |
| HPV vaccination status, n (%)                         |            |            |
| Yes   | 97 (42.7)  | 120 (51.3) |
| No  | 130 (57.3) | 114 (48.7) |
| Validated HPV vaccination status <sup>i</sup> , n (%) |            |            |
| Yes   | 47 (20.7)  | 61 (26.1)  |
| No  | 64 (28.2)  | 63 (26.9)  |
| Missing   | 116 (51.1) | 110 (47.0) |

Race categories with fewer than 5 participants in each group were collapsed to respect participants anonymity.

<sup>a,b,c</sup> Data were not reported by 2, 1, and 2 participants, respectively.

<sup>d</sup> Participant tested positive for at least 1 of 36 HPV types.

<sup>6</sup> Missing results correspond to invalid or mishandled samples. <sup>6</sup> Missing results correspond to invalid or mishandled samples. <sup>6</sup> Subgenus 1 group includes HPVs 6, 11, 40, 42, 44, and 54. <sup>8</sup> Subgenus 2 group includes HPVs 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, and 82. <sup>h</sup> Subgenus 3 group includes HPVs 61, 62, 71, 72, 81, 83, 84, and 89.

<sup>i</sup> Details of the validation of participants' vaccination status can be found in Supplmentary section 2 (Figure 2 and Tables 2A-2C). SD: standard deviation, IQR: interquartile range, PCR: polymerase chain reaction, HPV: human papillomavirus, DNA: deoxyribonucleic acid.

|                   | HPV infection<br>grouping |                                 | Carrag                                     | eenan                                       |                                 | Placebo                         |  |   |                                 | Effect<br>estimate       |  |
|-------------------|---------------------------|---------------------------------|--|---|---------------------------------|---------------------------------|--|---|---------------------------------|--------------------------|--|
| Analysis<br>level |                           | N incident/<br>N at risk<br>(%) | Actuarial<br>mean <sup>a</sup><br>(95% CI) | Arithmetic<br>mean <sup>a</sup><br>(95% CI) | Median <sup>a</sup><br>(95% CI) | N Incident/<br>N at risk<br>(%) | Actuarial<br>mean <sup>a</sup><br>(95% CI) | Arithmetic<br>mean <sup>a</sup><br>(95% CI) | Median <sup>a</sup><br>(95% CI) | Hazard ratio<br>(95% CI) |  |
|                   | Any HPV                   | 108/208                         | 12.6 <sup>b</sup>                          | 4.8   | 11.3                            | 147/221                         | $8 \cdot 7^{b}$                            | 3.5   | 3.7                             | 0.63                     |  |
|                   |                           | (51.9)                          | (10.6-14.7)                                | (3.8-5.7)                                   | (6.2-14.3)                      | (66.5)                          | $(7 \cdot 1 - 10 \cdot 3)$                 | $(2 \cdot 8 - 4 \cdot 2)$                   | (3.0-6.0)                       | (0.49-0.81)              |  |
|                   | Subgenus 1 <sup>c</sup>   | 33/208                          | 24.8 <sup>b</sup>                          | 6.6   | NR                              | 56/221                          | 22·7 <sup>b</sup>                          | 5.3   | NR                              | 0.58                     |  |
| Dentiducent       |                           | (15.9)                          | (22.9-26.7)                                | (4.8-8.3)                                   |                                 | (25.3)                          | (20.5 - 24.8)                              | (4.0-6.6)                                   | (17·8-) <sup>d</sup>            | (0.38-0.89)              |  |
| Participant       | Subgenus 2 <sup>e</sup>   | 84/208                          | 16·1 <sup>b</sup>                          | 5.0   | 14.9                            | 124/221                         | 11.1                                       | 4.4   | 8.6                             | 0.61                     |  |
|                   |                           | (40.4)                          | $(13 \cdot 8 - 18 \cdot 4)$                | (3.8-6.1)                                   | (12·6-) <sup>d</sup>            | (56.1)                          | (9.3-12.9)                                 | (3.6-5.3)                                   | (6.0-12.0)                      | (0.46-0.81)              |  |
|                   | Subgenus 3 <sup>f</sup>   | 55/208                          | 20·7 <sup>b</sup>                          | 5.7   | 23.7                            | 79/221                          | 19·2 <sup>b</sup>                          | 5.5   | 22.4                            | 0.70                     |  |
|                   |                           | (26.4)                          | $(18 \cdot 3 - 23 \cdot 1)$                | (4.2-7.3)                                   | (20·1-) <sup>d</sup>            | (35.8)                          | $(16 \cdot 8 - 21 \cdot 6)$                | (4.4-6.5)                                   | (13·6-) <sup>d</sup>            | (0.50-0.99)              |  |
| HPV               | A 11D179                  | 278/7,217                       | 29·1 <sup>b</sup>                          | 6.7   | NR                              | 438/7,586                       | 29.7 <sup>b</sup>                          | 6.4   | ND                              | 0.65                     |  |
| Hrv               | Any HPV <sup>g</sup>      | (3.9)                           | (28.9-29.3)                                | (6.0-7.3)                                   |                                 | (5.8)                           | (29.4-29.9)                                | (5.9-6.9)                                   | NR                              | (0.50-0.83)              |  |

#### Table 2. Incidence of any HPV infection and grouped infections at the participant- and HPV-level, by study arm

<sup>a</sup> Time in months. The actuarial mean accounts for censoring, whereas the arithmetic mean excludes participants who did not acquire a new HPV type.

<sup>b</sup>Mean was underestimated since the largest observed analysis time was censored.

<sup>c</sup> Subgenus 1 includes HPVs 6, 11, 40, 42, 44, and 54.

<sup>d</sup> Upper confidence limit was undetermined since the survival function did not fall below 0.5.

<sup>e</sup> Subgenus 2 includes HPVs 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, and 82.

<sup>f</sup> Subgenus 3 includes HPVs 61, 62, 71, 72, 81, 83, 84, and 89.

<sup>g</sup> Proportional hazards Cox regression models account for all incident HPV infections acquired over follow-up. Participants were considered at risk for any HPV type absent at baseline. Each participant could contribute up to 36 observations, each corresponding to an HPV type. The unit of analysis was each individual HPV type.

CI: confidence interval, HPV: human papillomavirus, NR: not reached, N: number

# Table 3. Clearance, according to outcome and definition, of any HPV infection at the participant- and HPV-level, by study arm

|                   | Unicome   | Clearance<br>definition <sup>a</sup> | Carrageenan                    |  |   |                                 | Placebo                        |  |   |                                 | Effect estimate             |  |
|-------------------|---|--------------------------------------|--------------------------------|--|---|---------------------------------|--------------------------------|--|---|---------------------------------|-----------------------------|--|
| Analysis<br>level |   |                                      | N cleared/<br>N at risk<br>(%) | Actuarial<br>mean <sup>b</sup><br>(95% CI) | Arithmetic<br>mean <sup>b</sup><br>(95% CI) | Median <sup>b</sup><br>(95% CI) | N cleared/<br>N at risk<br>(%) | Actuarial<br>mean <sup>b</sup><br>(95% CI) | Arithmetic<br>mean <sup>b</sup><br>(95% CI) | Median <sup>b</sup><br>(95% CI) | Hazard ratio<br>(95% CI)    |  |
|                   | Time to<br>clearance of all<br>HPV types <sup>c</sup>             | Liberal                              | 62/107<br>(57·9)               | 10·0<br>(8·4-11·6)                         | 5·4<br>(4·8-5·9)                            | 9·3<br>(6·4-11·0)               | 66/133<br>(49·6)               | 13·0<br>(10·9-15·0)                        | 5·8<br>(5·2-6·4)                            | 11·1<br>(9·5-13·4)              | $1 \cdot 41$<br>(0.99-2.00) |  |
| -                 |   | Conservative                         | 34/107<br>(31·8)               | $14 \cdot 8^{d}$<br>(13.0-16.6)            | 5.7<br>(5.0-6.5)                            | 16·0<br>(10·5-NR)               | 39/133<br>(29·3)               | 19·3<br>(16·8-21·7)                        | 6·2<br>(5·4-7·0)                            | 28·9<br>(13·6-NR)               | 1.16<br>(0.73-1.84)         |  |
| Participant       | Time to first<br>cleared HPV<br>infection <sup>e</sup>            | Liberal                              | 85/107<br>(79·4)               | $4.7^{d}$<br>(3.6-5.8)                     | 5·0<br>(4·6-5·5)                            | 3·0<br>(1·2-4·1)                | 105/133<br>(79·0)              | 4·8<br>(3·9-5·7)                           | 5·4<br>(4·9-5·8)                            | 3·2<br>(1·6-4·0)                | 1.03<br>(0.77-1.38)         |  |
|                   |   | Conservative                         | 67/107<br>(62·6)               | $6 \cdot 8^{d}$<br>(5 \cdot 4 - 8 \cdot 1) | 5·4<br>(4·9-6·0)                            | 6·0<br>(4·1-6·5)                | 81/133<br>(60·9)               | $7 \cdot 6^{d}$<br>(6 · 1 - 9 · 2)         | 5.7<br>(5.2-6.2)                            | 5·8<br>(3·2-6·9)                | 1.04<br>(0.75-1.44)         |  |
| HPV               | Time to<br>clearance of an<br>individual HPV<br>type <sup>f</sup> | Liberal                              | 181/271<br>(66·8)              | 0.24<br>(0.2-0.3)                          | 5.0<br>(4.2-5.7)                            | 0.20<br>(0.1-0.2)               | 243/370<br>(65·7)              | 0.29<br>(0.26-0.32)                        | 5.9<br>(5.3-6.5)                            | 0.23<br>(0.21-0.25)             | 1.17<br>(0.90-1.51)         |  |
| ΠĽV               |   | Conservative                         | 122/271<br>(45·0)              | 0.38 <sup>d</sup><br>(0.3-0.4)             | 5.1<br>(4.4-5.9)                            | 0.31<br>(0.3-0.4)               | 169/370<br>(45·7)              | 0.45<br>(0.40-0.50)                        | 5.6<br>(4.8-6.3)                            | 0.34<br>(0.27-0.38)             | 1.10<br>(0.84-1.43)         |  |

<sup>a</sup>Liberal clearance was defined as having a single HPV-negative visit following  $\geq$  1 HPV-positive visit(s). Conservative clearance was defined as having  $\geq$  2 consecutive HPV-negative visits following  $\geq$  1 HPV-positive visit(s).

<sup>b</sup> Time in months. The actuarial mean accounts for censoring, whereas the arithmetic mean excludes participants who did not acquire a new HPV type.

<sup>c</sup> Time to clearance of all baseline HPV infections (i.e., clearance was considered to have occurred once all baseline HPV infections cleared).

<sup>d</sup> Mean was underestimated since the largest observed analysis time was censored.

<sup>e</sup> Time to clearance of the first baseline HPV infection (i.e., clearance was considered to have occurred once the first of any baseline HPV infections cleared).

<sup>f</sup> Proportional hazards Cox regression models account for all baseline HPV types that cleared over follow-up. Participants were considered at risk for clearing any HPV type present at baseline. Each participant could contribute up to 36 observations, each corresponding to an HPV type. The unit of analysis was each individual HPV type.

CI: confidence interval, HPV: human papillomavirus, NR: not reached, N: number.

| Table 4. Adverse events [n (%)] reported through different sources, overall and by study |  |
|--|--|
| arm  |  |

|  | Overall<br>(n=461) | Carrageenan<br>(n=227) | Placebo<br>(n=234) | + (more AE<br>in CG arm) |
|--|--------------------|------------------------|--------------------|--------------------------|
| Any adverse event reported, overall <sup>a</sup>           | 172 (37.3)         | 79 (34.8)              | 93 (39.7)          |                          |
| ,  | ( )                |                        |                    |                          |
| 1. Daily calendar <sup>b</sup>                             | 76 (17.6)          | 37 (17.8)              | <b>39</b> (17·3)   |                          |
| Unusually heavy or painful period                          | 9 (2.1)            | 1 (0.5)                | 8 (3.6)            |                          |
| Vaginal bleeding in between menstrual periods              | 14 (3.2)           | 6 (2.9)                | 8 (3.6)            |                          |
| Pain during vaginal sex <sup>c</sup>                       | 19 (4.8)           | 13 (6.9)               | 6 (2.9)            | +                        |
| Unusual vaginal discharge                                  | 15 (3.5)           | 11 (5.3)               | 4 (1.8)            | +                        |
| Itching, burning, or pain in the genital area              | 42 (9.7)           | 23 (11.1)              | 19 (8.4)           | +                        |
| Genital sore/ulcer   | 5 (1.2)            | 2 (1.0)                | 3 (1.3)            |                          |
| Needing to urinate more often than usual                   | 10 (2.3)           | 3 (1.4)                | 7 (3.1)            |                          |
| Pain while urinating                                       | 9 (2.1)            | 6 (2.9)                | 3 (1.3)            | +                        |
| Blood in urine   | 4 (0.9)            | 3 (1.4)                | 1 (0.4)            | +                        |
| Lower abdominal pain                                       | 8 (1.9)            | 5 (2.4)                | 3 (1.3)            | +                        |
| Lower back pain not caused by physical exertion            | 2(0.5)             | 0 (0)                  | 2(0.9)             |                          |
| Other <sup>d</sup>   | 42 (9.7)           | 21 (10.1)              | 21 (9.3)           | +                        |
| 2.1 Follow-up survey <sup>e</sup>                          | 55 (13.0)          | 24 (11.7)              | 31 (14.2)          |                          |
| Gel use caused discomfort/adverse reactions to participant | 49 (11.6)          | 22 (10.7)              | 27 (12.4)          |                          |
| Gel use caused discomfort/adverse reactions to partner     | $10(2 \cdot 4)$    | 5 (2.4)                | 5 (2.3)            | +                        |
| 2.2 Follow-up survey, conditions <sup>f</sup>              | <b>91</b> (21·3)   | 43 (20.7)              | 48 (21·8)          |                          |
| Vaginal yeast infection                                    | 70 (16.5)          | 35 (17.0)              | 35 (16.0)          | +                        |
| Trichomonas vaginal infection                              | 6 (1.4)            | 3 (1.5)                | 3 (1.4)            | +                        |
| Venereal warts, condyloma, or HPV                          | 10 (2.3)           | 5 (2.4)                | 5 (2.3)            | +                        |
| Chlamydia  | 12 (2.8)           | 6 (2.9)                | 6 (2.7)            | +                        |
| Genital herpes   | 8 (1.9)            | 3 (1.4)                | 5 (2.3)            |                          |
| Syphilis   | 4 (0.9)            | 2 (1.0)                | 2(0.9)             | +                        |
| Gonorrhea  | 4 (0.9)            | 2 (1.0)                | 2 (0.9)            | +                        |
| Ulcers or genital sores                                    | 5 (1.2)            | 2 (1.0)                | 3 (1.4)            |                          |
| Human immunodeficiency virus                               | 4 (0.9)            | 2 (1.0)                | 2 (0.9)            | +                        |
| Hepatitis B  | 4 (0.9)            | 2 (1.0)                | 2(0.9)             | +                        |
| Bacterial vaginosis  | 24 (5.6)           | 11 (5.3)               | 13 (5.9)           |                          |
| 3. Adverse event module (nurse report) <sup>g</sup>        | 75 (16·3)          | 38 (16.7)              | 37 (15.8)          | +                        |
| Unusually heavy or painful period                          | 6 (1.3)            | 1(0.4)                 | 5 (2.1)            |                          |
| Vaginal bleeding in between menstrual periods              | 13 (2.8)           | 5 (2.2)                | 8 (3.4)            |                          |
| Pain during vaginal sex                                    | 18 (3.9)           | 12 (5.3)               | 6 (2.6)            | +                        |
| Unusual vaginal discharge                                  | 14 (3.0)           | 10 (4.4)               | 4 (1.7)            | +                        |
| Itching, burning, or pain in the genital area              | 43 (9.3)           | 24 (10.6)              | 19 (8.1)           | +                        |
| Genital sore/ulcer   | 5 (1.1)            | 2 (0.9)                | 3 (1.3)            |                          |
| Needing to urinate more often than usual                   | 8 (1.7)            | 3 (1.3)                | 5 (2.1)            |                          |
| Pain while urinating                                       | 9 (2.0)            | 6 (2.6)                | 3 (1.3)            | +                        |
| Blood in urine   | 4 (0.9)            | 3 (1.3)                | 1 (0.4)            | +                        |
| Lower abdominal pain                                       | 6 (1.3)            | 4 (1.8)                | 2 (0.9)            | +                        |
| Lower back pain not caused by physical exertion            | 2 (0.4)            | 0 (0)                  | 2 (0.9)            |                          |
| Other <sup>d</sup>   | 25 (5.4)           | 11 (4.9)               | 14 (6.0)           |                          |
| 4. Adverse event follow-up <sup>g</sup>                    | 20 (4.3)           | 9 ( <b>4</b> ·0)       | 11 (4.7)           |                          |

The percentage of adverse events was calculated as the number of participants affected by an AE divided by the number of participants who ever responded to the question. The protocol did not specify conditions would be included as AE.

<sup>a</sup> 15 participants in the carrageenan and 5 participants in the placebo arm never provided any information about adverse events. These participants only had 1 visit. However, these 20 participants were included in the calculation of any adverse reported overall, as for two sources (Adverse event module [nurse report] and (Adverse event follow-up), due to the nature of reporting, we used an inferred denominator that included all participants randomized.

<sup>b</sup> 28 participants were not included: 19 participants in the carrageenan arm and 9 participants in the placebo group never filled out the calendar.

<sup>c</sup> 63 participants were not included: 19 participants in the carrageenan and 16 participants in the placebo arm did not report intercourse, and 19 participants in the carrageenan arm and 9 participants in the placebo group never filled out the calendar.

<sup>d</sup> Other AEs reported included burning, irritation, urinary tract infection, spotting, and yeast infection among others.


<sup>e</sup> 37 participants were not included: 32 participants did not have a follow-up visit (19 in the carrageenan and 13 in the placebo group) and 5 participants (2 in the carrageenan arm and 3 in the placebo arm) did not respond to these questions in the follow-up survey.

<sup>1</sup> 33 participants were not included overall: 32 participants did not have a follow-up visit (19 in the carrageenan and 13 in the placebo group) and 1 participant (1 in the placebo group) did not respond to any of these questions in the follow-up survey.

<sup>g</sup> Due to the nature of reporting we used an inferred denominator, which included all participants randomized.


N: number of participants affected, +: a greater proportion of adverse events were reported in the carrageenan arm relative to the placebo arm, AE: adverse event, HPV: human papillomavirus.





# Figure 1 legend

The CONSORT flow diagram displays the total number of participants assessed for eligibility who were subsequently enrolled and randomised into either the carrageenan or placebo arm. Reasons for exclusion and discontinuing the intervention are provided. A total of 429 participants were included in the incidence analyses, 240 in the clearance analyses, and 461 in the safety analysis.



#### Figure 2. Cumulative incidence/detection of HPV at the participant- and HPV-level

# **Figure 2 legend**

Fig2A plots the first HPV infection episode detected using women as the unit of observation (i.e., participant-level analysis); the number at risk corresponds to the number of women who were HPV-negative for at least 1 of the 36 HPV types at baseline. Fig2B plots all new HPV infections based on HPV-level analysis; the number at risk corresponds to the number of infections a participant could have acquired at subsequent visits. Each participant could have acquired any of the 36 HPV types for which they were negative at baseline.